Hims & Hers Remains Optimistic on Weight Loss Business -- Market Talk

Dow Jones

Nov 12, 2025

1852 ET - Hims & Hers Health is still optimistic about the value proposition and future growth of its weight-loss business after the Trump administration said it would offer Wegovy and Zepbound on the TrumpRx platform, Truist Securities analysts say in a note after meeting with management. Hims & Hers sees its compounded GLP-1 subscription offering significantly more value. Its $199 price is lower than the average $350 per month price point on TrumpRx, and it includes prescription, personalization and access to a provider in addition to the medication itself, the analysts say. "HIMS emphasized that true accessibility also requires a seamless, outcome-driven customer experience, which it believes its platform uniquely delivers," the analysts say. (kelly.cloonan@wsj.com)

(END) Dow Jones Newswires

November 11, 2025 18:52 ET (23:52 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2582316804"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582316804\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582316804?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-12 07:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582316804","market":"other","top_or_hot":-1,"title":"Hims & Hers Remains Optimistic on Weight Loss Business -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1852 ET - Hims &amp; Hers Health is still optimistic about the value proposition and future growth of its weight-loss business after the Trump administration said it would offer Wegovy and Zepbound on the TrumpRx platform, Truist Securities analysts say in a note after meeting with management. Hims &amp; Hers sees its compounded GLP-1 subscription offering significantly more value. Its $199 price is lower than the average $350 per month price point on TrumpRx, and it includes prescription, personalization and access to a provider in addition to the medication itself, the analysts say. \"HIMS emphasized that true accessibility also requires a seamless, outcome-driven customer experience, which it believes its platform uniquely delivers,\" the analysts say. (kelly.cloonan@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 11, 2025 18:52 ET (23:52 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hims & Hers Remains Optimistic on Weight Loss Business -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHims & Hers Remains Optimistic on Weight Loss Business -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-11-12 07:52</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1852 ET - Hims &amp; Hers Health is still optimistic about the value proposition and future growth of its weight-loss business after the Trump administration said it would offer Wegovy and Zepbound on the TrumpRx platform, Truist Securities analysts say in a note after meeting with management. Hims &amp; Hers sees its compounded GLP-1 subscription offering significantly more value. Its $199 price is lower than the average $350 per month price point on TrumpRx, and it includes prescription, personalization and access to a provider in addition to the medication itself, the analysts say. \"HIMS emphasized that true accessibility also requires a seamless, outcome-driven customer experience, which it believes its platform uniquely delivers,\" the analysts say. (kelly.cloonan@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 11, 2025 18:52 ET (23:52 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4196","symbol_name":"保健护理服务","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2582316804","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582316804","pubTimestamp":1762905120,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1852 ET - Hims & Hers Health is still optimistic about the value proposition and future growth of its weight-loss business after the Trump administration said it would offer Wegovy and Zepbound on the TrumpRx platform, Truist Securities analysts say in a note after meeting with management. Hims & Hers sees its compounded GLP-1 subscription offering significantly more value. Its $199 price is lower than the average $350 per month price point on TrumpRx, and it includes prescription, personalization and access to a provider in addition to the medication itself, the analysts say. \"HIMS emphasized that true accessibility also requires a seamless, outcome-driven customer experience, which it believes its platform uniquely delivers,\" the analysts say. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4196":"保健护理服务","HIMS":"Hims & Hers Health Inc."},"translate_title":"Hims&Hers对减肥业务保持乐观——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":0.9},"content_text":"1852 ET - Hims & Hers Health is still optimistic about the value proposition and future growth of its weight-loss business after the Trump administration said it would offer Wegovy and Zepbound on the TrumpRx platform, Truist Securities analysts say in a note after meeting with management. Hims & Hers sees its compounded GLP-1 subscription offering significantly more value. Its $199 price is lower than the average $350 per month price point on TrumpRx, and it includes prescription, personalization and access to a provider in addition to the medication itself, the analysts say. \"HIMS emphasized that true accessibility also requires a seamless, outcome-driven customer experience, which it believes its platform uniquely delivers,\" the analysts say. (kelly.cloonan@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 11, 2025 18:52 ET (23:52 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}